Melatonin promotes proliferation and expression of chondrocyte marker genes of Slc26a2-deficient chondrocytes. (IMAGE)
Caption
(A) Primary chondrocyte cells were subjected to treatment with different melatonin concentrations, spanning from 0.1 to 100 μM, for 72 h. CCK8 assay revealed that 0.1, 10, and 50 μM melatonin treatments had no impact on cell viability, and the viability of cells notably decreased with the application of 100 μM melatonin. (B) The recorded cell morphology of each group was representative. Scale bars, 200 μm. (C) Ki67 immunostaining of chondrocytes. Scale bars, 200 μm. (D–F) Immunofluorescent assessments were conducted on chondrogenic markers SOX9, COL II, and ACAN. Scale bars, 200 μm. (G) Measurement of cells expressing Ki67 and SOX9 and chondrocytes labeled with COL II and ACAN. (H) Real-time quantitative PCR was employed to analyze the expression levels of Sox9, Col2a1, and Acan mRNA. Statistical significance was assessed through One-way ANOVA followed by Tukey's multiple comparisons test. The results are presented as mean ± standard deviation, with ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001 indicating statistical significance, while “ns” denotes no statistical significance. SOX9, SRY-box transcription factor 9; COL II, collagen type II; ACAN, aggrecan; SLC26A2, Solute carrier family 26 member 2; CTR, cre-negative control.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND